Kyushu University Academic Staff Educational and Research Activities Database
List of Papers
hitoshi kusaba Last modified date:2021.10.25

Associate Professor / Department of Medicine and Biosystemic Science Faculty of Medicine / Department of Clinical Medicine / Faculty of Medical Sciences


Papers
1. Nakajima H, Fukuoka S, Masuishi T, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Negoro Y, Komoda M, Makiyama A, Denda T, Hatachi Y, Suto T, Sugimoto N, Enomoto M, Ishikawa T, Kashiwada T, Ando K, Yuki S, Okuyama H, Kusaba H, Sakai D, Okamoto K, Tamura T, Yamashita K, Gosho M, Moriwaki T. , Clinical Impact of Primary Tumor Location in Metastatic Colorectal Cancer Patients Under Later-Line Regorafenib or Trifluridine/Tipiracil Treatment. , Front Oncol. , doi: 10.3389/fonc.2021.688709, 15, 11, 688709. , 2021.06.
2. N Akiyama, T Okamura, M Yoshida, S Kimura, S Yano, I Yoshida, H Kusaba, K Takahashi, H Fujita, K Fukushima, H Iwasaki, K Tamura, T Saeki, Y Takamatsu, S Zenda. , A questionnaire survey on evaluation for penetration and compliance of the Japanese Guideline on Febrile Neutropenia among hematology‑oncology physicians and surgeons. , Supportive Care Cancer , 10.1007/s00520-021-06277-8, 2021.05.
3. Chida K, Kotani D, Moriwaki T, Fukuoka S, Masuishi T, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Komoda M, Makiyama A, Denda T, Hatachi Y, Suto T, Sugimoto N, Enomoto M, Ishikawa T, Kashiwada T, Ando K, Yuki S, Okita Y, Kusaba H, Sakai D, Okamoto K, Tamura T, Yamashita K, Gosho M, Shimada Y. , Survival Benefit of Crossover Administration of Regorafenib and Trifluridine/ Tipiracil Hydrochloride for Patients with Metastatic Colorectal Cancer: Exploratory Analysis of a Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study (REGOTAS). , Front Oncol. , 10.3389/fonc.2021.576036, 8, 11, 576036, 2021.03.
4. Tanoue K, Tamura S, Kusaba H, Shinohara Y, Ito M, Tsuchihashi K, Shirakawa T, Otsuka T, Ohmura H, Isobe T, Ariyama H, Koreishi S, Matsushita Y, Shimokawa H, Tanaka R, Mitsugi K, Akashi K, Baba E. , Predictive impact of C-reactive protein to albumin ratio for recurrent or metastatic head and neck squamous cell carcinoma receiving nivolumab. , Sci Rep. , 11, 1, 2741, 2021.01.
5. Tsuchihashi K, Kusaba H, Yoshihiro T, Fujiwara T, Setsu N, Endo M, Matsumoto Y, Imajima T, Shinohara Y, Ito M, Yamaga S, Tanoue K, Arimizu K, Ohmura H, Hanamura F, Yamaguchi K, Isobe T, Ariyama H, Nakashima Y, Akashi K, Baba E. , Eribulin as a first-line treatment for soft tissue sarcoma patients with contraindications for doxorubicin. , Sci Rep. , 10, 1, 20896, 2020.10.
6. Hosokawa A, Yamazaki K, Matsuda C, Ueda S, Kusaba H, Okamura S, Tsuda M, Tamura T, Shinozaki K, Tsushima T, Tsuda T, Shirakawa T, Yamashita H, Morita S, Hironaka S, Muro K., Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases: A post hoc analysis of the WJOG4407G phase III study., Medicine, 99, 36, e22060, 2020.08.
7. S Moriyama, M Fukata, H Kusaba, T Maruyama, K Akashi. , Acute and Chronic Effects of Cancer Drugs on the Cardiovascular System. , Heart Failure Clin , 16, 231-241, 2020.04.
8. Ohmura H, Ito M, Uchino K, Okada C, Tanishima S, Yamada Y, Momosaki S, Komoda M, Kuwayama M, Yamaguchi K, Okumura Y, Nakano M, Tsuchihashi K, Isobe T, Ariyama H, Kusaba H, Oda Y, Akashi K, Baba E., Methylation of drug resistance-related genes in chemotherapy-sensitive Epstein-Barr virus-associated gastric cancer., FEBS Open Biology, 10, 1, 2020.02.
9. N Tsuruta, K Tsuchihashi, H Ohmura, K Yamaguchi,M Ito, H Ariyama, H Kusaba, K Akashi, E Baba., RNA N6-methyladenosine demethylase FTO regulates PD-L1 expression in colon cancer cells., Biochemical and Biophysical Research Communications, 530, 235-239, 2020.10.
10. Suzuki K, Yanagihara T, Matsumoto K, Kusaba H, Yamauchi T, Ikematsu Y, Tanaka K, Otsubo K, Inoue H, Yoneshima Y, Iwama E, Arimura-Omori M, Harada E, Hamada N, Okamoto I, Nakanishi Y. , Immune-checkpoint profiles for T cells in bronchoalveolar lavage fluid of patients with immune-checkpoint inhibitor-related interstitial lung disease. , Int Immunol. , 32, 8, 547-557, 2020.08.
11. H Ohmura, K Yamaguchi, F Hanamura, M Ito, A Makiyama, K Uchino, H Shimokawa, S Tamura, T Esaki, K Mitsugi, Y Shibata, H Oda, K Tsuchihashi, H Ariyama, H Kusaba, Y Oda, K Akashi, E Baba., OX40 and LAG3 are associated with better prognosis in advanced gastric cancer patients treated with anti-programmed death-1 antibody., Br J Cancer, 122, 1507-1517, 2020.03.
12. Yamaguchi K, Ito M, Ohmura H, Hanamura F, Nakano M, Tsuchihashi K, Nagai S, Ariyama H, Kusaba H, Yamamoto H, Oda Y, Nakamura M, Akashi K, Baba E. , Helper T cell-dominant tertiary lymphoid structures are associated with disease relapse of advanced colorectal cancer. , Oncoimmunology, 9, 1, 1724763, 2020.01.
13. Yoshihiro T, Kusaba H, Makiyama A, Kobayashi K, Uenomachi M, Ito M, Doi Y, Mitsugi K, Aikawa T, Takayoshi K, Esaki T, Shimokawa H, Tsuchihashi K, Ariyama H, Akashi K, Baba E. , Efficacy and safety of ramucirumab plus modified FOLFIRI for metastatic colorectal cancer. , Int J Clin Oncol. , 24, 5, 508-515, 2019.10.
14. Takayoshi K, Kusaba H, Aikawa T, Koreishi S, Sagara K, Nakano M, Komoda M, Kono M, Fukata M, Arita T, Esaki T, Akashi K, Baba E. , Hypoalbuminemia for the prediction of venous thromboembolism and treatment of direct oral anticoagulants in metastatic gastric cancer patients. , Gastric Cancer, 22, 5, 988-998, 2019.04.
15. Nakano M, Kikushige Y, Miyawaki K, Kunisaki Y, Mizuno S, Takenaka K, Tamura S, Okumura Y, Ito M, Ariyama H, Kusaba H, Nakamura M, Maeda T, Baba E, Akashi K., Dedifferentiation process driven by TGF-beta signaling enhances stem cell properties in human colorectal cancer., Oncogene., 38, 6, 780-793, 2019.06.
16. K Yamaguchi, H Kusaba, A Makiyama, K Mitsugi, K Uchino, S Tamura, Y Shibata, T Esaki, M Ito, K Takayoshi, K Tsuchihashi, S Arita, H Ariyama, K Akashi, E Baba, The risk factors for oxaliplatin-induced peripheral sensory neuropathy and thrombocytopenia in advanced gastric cancer., Cancer Chemotherapy and Pharmacology, 82, 4, 625-633, 2018.06.
17. Kumagai H, Kusaba H, Yamanaka T, Nio K, Inadomi K, Takayoshi K, Ito M, Tamura S, Makiyama A, Makiyama C, Hirano G, Shibata Y, Shirakawa T, Mitsugi K, Ariyama H, Esaki T, Akashi K, Baba E., A phase 2 study of fosaprepitant combined with high-dose dexamethasone for Japanese cancer patients receiving highly emetogenic chemotherapy. , Medicine, 97, 25, e11042, 2018.05.
18. Makiyama A, Arimizu K, Hirano G, Makiyama C, Matsushita Y, Shirakawa T, Ohmura H, Komoda M, Uchino K, Inadomi K, Arita S, Ariyama H, Kusaba H, Shinohara Y, Kuwayama M, Kajitani T, Oda H, Esaki T, Akashi K, Baba E., Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer., Gastric Cancer, 21, 3, 464-472, 2018.04.
19. Nakano M, Ito M, Tanaka R, Ariyama H, Mitsugi K, Makiyama A, Uchino K, Esaki T, Tsuruta N, Hanamura F, Yamaguchi K, Okumura Y, Sagara K, Takayoshi K, Nio K, Tsuchihashi K, Tamura S, Shimokawa H, Arita S, Miyawaki K, Kusaba H, Akashi K, Baba E. , Epithelial-mesenchymal transition is activated in CD44-positive malignant ascites tumor cells of gastrointestinal cancer. , Cancer Sci. , 109, 11, 3461-3470, 2018.11.
20. Yamaguchi K, Mishima K, Ohmura H, Hanamura F, Ito M, Nakano M, Tsuchihashi K, Ota SI, Wada N, Uchi H, Ariyama H, Kusaba H, Niiro H, Akashi K, Baba E. , Activation of central/effector memory T cells and Th1 polarization in malignant melanoma patients treated with anti-PD-1 antibody. , Cancer Sci. , 109 , 10, 3032-3042, 2018.10.
21. Nakano M, Ito M, Tanaka R, Yamaguchi K, Ariyama H, Mitsugi K, Yoshihiro T, Ohmura H, Tsuruta N, Hanamura F, Sagara K, Okumura Y, Nio K, Tsuchihashi K, Arita S, Kusaba H, Akashi K, Baba E. , PD-1+ TIM-3+ T cells in malignant ascites predict prognosis of gastrointestinal cancer. , Cancer Sci. , 109, 9, 2986-2992, 2018.09.
22. Tamura S, Isobe T, Ariyama H, Nakano M, Kikushige Y, Takaishi S, Kusaba H, Takenaka K, Ueki T, Nakamura M, Akashi K, Baba E. , E cadherin regulates proliferation of colorectal cancer stem cells through NANOG. , Oncol Rep., 40, 2, 693-703, 2018.02.
23. Ito M, Kusaba H, Mukaide S, Kishimoto J, Shimokawa H, Tamura S, Makiyama A, Hirano G, Oda H, Shirakawa T, Komoda M, Uchino K, Mitsugi K, Esaki T, Arita S, Ariyama H, Akashi K, Baba E., Early tumor shrinkage indicates a favorable response to bevacizumab-based first-line chemotherapy for metastatic colorectal cancer., Anticancer Drugs., 28, 10, 1166-1173, 2017.10.
24. Takayoshi K, Kusaba H, Uenomachi M, Mitsugi K, Makiyama C, Makiyama A, Uchino K, Shirakawa T, Shibata Y, Shinohara Y, Inadomi K, Tsuchihashi K, Arita S, Ariyama H, Esaki T, Akashi K, Baba E., Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer., Cancer Chemotherapy and Pharmacology, 80, 2, 333-342, 2017.04.
25. Inadomi K, Kusaba H, Matsushita Y, Tanaka R, Mitsugi K, Arimizu K, Hirano G, Makiyama A, Ohmura H, Uchino K, Hanamura F, Shibata Y, Kuwayama M, Esaki T, Takayoshi K, Arita S, Ariyama H, Akashi K, Baba E. , Efficacy and Safety Analysis of Oxaliplatin-based Chemotherapy for Advanced Gastric Cancer. , Anticancer Res, 37, 2663-2671, 2017.02.
26. Kusaba H, Kumagai H, Inadomi K, Matsunobu T, Harimaya K, Takayoshi K, Arita S, Ariyama H, Akashi K, Baba E. , Efficacy analysis of the aprepitant-combined antiemetic prophylaxis for non-round cell soft-tissue sarcoma patients received adriamycin and ifosfamide therapy. , Medicine, 95, 49, e5460, 2016.09.
27. Tsuyoshi Shirakawa, M Nakano, K Nio, Shingo Tamura, Masato Komoda, Hozumi Kumagai, Keita Uchino, Keita Odashiro, Shuji Arita, Ariyama Hiroshi, hitoshi kusaba, koichi akashi, Eishi Baba, Retrospective analysis of cardiovascular diseases related to chemotherapies for advanced solid tumor patients., Anticancer Drugs, 27, 891-898, 2016.05.
28. Shuji Arita, hitoshi kusaba, Eishi Baba, koichi akashi, Esaki T, Tamura S, Mitsugi K, Ariyama Hiroshi, Shimokawa HK, Yoshihiro Shibata, Shirakawa T, Matsushita Y, Hirano G, Makiyama A, Efficacy and Safety of TAS-102 in Clinical Practice of Salvage Chemotherapy for Metastatic Colorectal Cancer. , Anticancer Res., 36, 4, 1959-1966, 2016.03.
29. Kenta Nio, hitoshi kusaba, Eishi Baba, Shuji Arita, koichi akashi, Esaki T, Daijiro Higashi, Kitaro Futami, Mitsugi K, Yoshinao Oda, Ariyama Hiroshi, Manabe Tatsuya, Takashi Ueki, Hozumi Kumagai, Yoshihiro Shibata, Efficacy and safety analysis of chemotherapy for advanced colitis-associated colorectal cancer in Japan., Anti-Cancer Drugs, 75, 2016.01.
30. K Nio, hitoshi kusaba, Ariyama Hiroshi, Eishi Baba, Shuji Arita, koichi akashi, Kenichi Kohashi, Esaki T, Makiyama A, Hirano G, Mitsugi K, Kajitani T, Tamura S, Amrubicin monotherapy for patients with extrapulmonary neuroendocrine carcinoma after platinum-based chemotherapy., Cancer Chemotherapy and Pharmacology, 75, 4, 829-835, 2015.04.
31. G HIRANO, A MAKIYAMA, C MAKIYAMA, TAITO ESAKI, K UCHINO, MASATO KOMODA, KENJI MITSUGI, Shuji Arita, Ariyama Hiroshi, hitoshi kusaba, koichi akashi, Eishi Baba, Reduced Dose of Salvage-line Regorafenib Monotherapy for Metastatic Colorectal Cancer in Japan., Anticancer Res., 35, 1, 371-377, 2015.02.
32. Hironaka S, Tsubosa Y, Mizusawa J, Kato K, Tsushima T, Chin K, Tomori A, Okuno T, Ura T, hitoshi kusaba, Nakamura T, Kitagawa Y, Phase I/II trial of 2-weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807). , Cancer Sci , 105, 1189-1195, 2014.09.
33. TAICHI ISOBE, KEITA UCHINO, Ariyama Hiroshi, Shuji Arita, SHINGO TAMURA, MASATO KOMODA, hitoshi kusaba, TAITO ESAKI, KENJI MITSUGI, Shigeo Takaishi, koichi akashi, Eishi Baba, Analysis of Adverse Events of Bevacizumab-containing Systemic Chemotherapy for Metastatic Colorectal Cancer in Japan. , Anticancer Res. , 34, 2035-2040, 2014.08.
34. Hozumi Kumagai, hitoshi kusaba, Yuta Okumura, Masato Komoda, Michitaka Nakano, Shingo Tamura, Shuji Arita, Ariyama Hiroshi, koichi akashi, Eishi Baba, Efficacy and Safety of an Increased-dose of Dexamethasone in Patients Receiving Fosaprepitant Chemotherapy in Japan. , Asian Pac J Cancer Prev, 15, 1, 459-463, 2014.05.
35. 田村真吾, hitoshi kusaba, 土橋 賢司, 薦田 正人, 内野 慶太, Ariyama Hiroshi, koichi akashi, Eishi Baba, Interstitial pneumonia during bevacizumab-based chemotherapy for colorectal cancer. , Medical Oncology, 31, 3, 856, 2014.05.
36. 草場 仁志, 江崎 泰斗, Junji Kishimoto, 内野 慶太, Shuji Arita, 三ツ木 健二, Koichi Akashi, Eishi Baba, Phase I study of bevacizumab combined with irinotecan and S-1 as second-line chemotherapy in patients with advanced colorectal cancer. , Cancer Chemother Pharmacol., 71, 1, 29-34, 2013.01, The combination of an oral fluoropyrimidine derivative, S-1, and irinotecan has been reported to be a promising regimen for advanced colorectal cancer. However, the safety and efficacy of bevacizumab (BV) to combine with irinotecan and S-1 has not been determined. The aim of the study was to determine the maximum tolerated dose (MTD) and recommended dose (RD) of BV combined with irinotecan plus S-1, and to observe the safety and efficacy of this regimen as second-line chemotherapy in patients with advanced colorectal cancer.
METHODS:This study initially had been planned as a phase I/II study. Eighty mg/m(2) of irinotecan on days 1 and 8, 80 mg/m(2) of S-1 for 14 consecutive days, and two doses of BV (Level 1; 10 mg/kg, Level -1; 7.5 mg/kg) were administered on day 1 every 3 weeks.
RESULTS:Fourteen patients were enrolled in phase I of the study between January 2008 and September 2010. Dose-limiting toxicities were diarrhea, abdominal pain, and infection. The MTD and RD of BV were determined to be 10 mg/kg and 7.5 mg/kg, respectively. The main adverse events were leukopenia, anorexia, and diarrhea. There were no treatment-related deaths. An independent review committee was scheduled to evaluate safety in phase I, but this trial closed early due to toxicity.
CONCLUSIONS:This study identified the risk of gastrointestinal toxicity with the combination of irinotecan, S-1 and BV as second-line chemotherapy in patients with advanced colorectal cancer..
37. Uchino K, Hirano G, Hirahashi M, Isobe T, Shirakawa T, Kusaba H, Baba E, Tsuneyoshi M, Akashi K. , Human Nanog pseudogene8 promotes the proliferation of gastrointestinal cancer cells. , Exp Cell Res., 318, 15, 1799-1807, 2012.05.
38. Eishi Baba • Hiromitsu Fujishima • Akitaka Makiyama • Keita Uchino • Risa Tanaka • Taito Esaki •Hitoshi Kusaba • Kenji Mitsugi • Shuji Nakano • Koichi Akashi. , Phase 2 Study of Modified Irinotecan and Bolus 5-Fluorouracil/l-Leucovorin in Japanese Metastatic Colorectal Cancer Patient. , Advances in Therapy, 1, 1-10, 2012.01.
39. Keita Uchino, Hitoshi Kusaba, Junji Kishimoto, Hiroshi Mitsuyasu, Hiroaki Kawasaki, Eishi Baba, and Koichi Akashi., Validation of Hospital Anxiety and Depression scale as a screening tool for Psychological distress in advanced cancer patients undergoing chemotherapy., Palliative Care Research, 6, 2, 150-156, 2011.10.
40. T. Isobe, E. Baba, S. Arita, M. Komoda, S. Tamura, T. Shirakawa, H. Ariyama, S. Takaishi, H. Kusaba, T. Ueki, K. Akashi. , Human STEAP3 maintains tumor growth under hypoferric condition. , Experimental Cell Research, 317, 2582-2591, 2011.11.
41. Gen Hirano, Hiroto Izumi, Yoshihiro Yasuniwa, Shohei Shimajiri, Wang Ke-Yong, Yasuyuki Sasagiri, Hitoshi Kusaba, Kaori Matsumoto,Tetsuya Hasegawa, Masayuki Akimoto, Koichi Akashi and Kimitoshi Kohno. , Involvement of riboflavin kinase expression in cellular sensitivity against cisplatin., Int J Oncol, 2011.03.
42. Ken Kato, Yoshitaka Inaba, Yasushi Tsuji, Taito Esaki, Akira Yoshioka, Nobuyuki Mizunuma,Toshiro Mizuno, Hitoshi Kusaba, Hirohumi Fujii, Kei Muro, Yasuhiro Shimada and Kuniaki Shirao. , A Multicenter Phase-II Study of 5-FU, Leucovorin and Oxaliplatin (FOLFOX6) in Patients with Pretreated Metastatic Colorectal Cancer., Jpn J Clin Oncol., 41, 1, 63-8, 2011.01.
43. Baba E, Esaki T, Ariyama H, Mitsugi K, Morikita T, Fujishima H, Kusaba H, Nakano S, Akashi K., Phase II study of sequential treatment with S-1 and cisplatin for metastatic gastric cancer., Cancer Chemotherapy and Pharmacology, 2010.11.
44. Hitoshi Kusaba, Taito Esaki, Kitaro Futami, Sinnosuke Tanaka, Hiromitsu Fujishima, Kenji Mitsugi, Kenji Sakai, Hiroshi Ariyama, Risa Tanaka, Naoko Kinugawa, Takashi Ueki, Rhuichi Mibu, Eishi Baba, Shuji Nakano, Koichi Akashi, Phase I/II study of a 3-week cycle Irinotecan and S-1 in patients with advanced colorectal cancer., Cancer Science, 101, 12, 2591-5, 2010.12.
45. Hirano G, Izumi H, Kidani A, Yasuniwa Y, Han B, Kusaba H, Akashi K, Kuwano M, Kohno K., Enhanced expression of PCAF endows apoptosis resistance in cisplatin-resistant cells., Mol Cancer Res. , 8, 6, 864-72, 2010.10.
46. Shibata Y, Ariyama H, Baba E, Takii Y, Esaki T, Mitsugi K, Tsuchiya T, Kusaba H, Akashi K, Nakano S. , Oxaliplatin-induced allergic reaction in patients with colorectal cancer in Japan. , Int J Clin Oncol., 14, 5, 397-401, 2009.11.
47. Taichi Isobe, Shunichi Yanai, Hitoshi Kusaba, Shinichiro Yada, Yosuke Kuroda, Sadafumi Tamiya, Takayuki Matsumoto, Eishi Baba, Mine Harada. , Effective monotherapy with amrubicin for a refractory extrapulmonary small-cell carcinoma of the liver. , Case Report of Medicine., 2009.07.
48. Baba E, Fujishima H, Kusaba H, Esaki T, Ariyama H, Kato K, Tanaka R, Mitsugi K, Shibata Y, Harada M, Nakano S. , Phase I study of the sequential administration of s-1 and Cisplatin for metastatic gastric cancer. , Anticancer Res. , 29(5):1727-32., 2009.05.
49. Makiyama A, Qin B, Uchino K, Shibata Y, Arita S, Isobe T, Hirano G, Kusaba H, Baba E, Akashi K, Nakano S., Schedule-dependent synergistic interaction between gemcitabine and oxaliplatin in human gallbladder adenocarcinoma cell lines., Anticancer Drugs., 20:123-30. 2009 , 2009.02.
50. Arita S, Baba E, Shibata Y, Niiro H, Shimoda S, Isobe T, Kusaba H, Nakano S, Harada M., B cell activation regulates exosomal HLA production.
, Eur J Immunol., 38:1423-34., 2008.06.
51. Y.Shibata, E.Baba, H.Ariyama, R.Miki, N.Ogami, S.Arita, B.Qin, H.Kusaba, K.MItsugi, H.Noshiro, T.Yao, S.Nakano, Metastatic basaloid-squamous cell carcinoma of the esophagus treated by 5-FU and cisplatin. , World J. Gastroenterology , 13, 3634-3637, 2007.08.
52. H. Kusaba, Y. Shibata, S. Arita, H. Ariyama, E. Baba, K. Mitsugi, M.Harada, S. Nakano, Infusional 5-fluorouracil and cisplatin as a front-line chemotherapy in patients with carcinoma of unknown primary site. , Medical Oncology, 24, 259-264., 2007.04.
53. Qin B, Tanaka R, Shibata Y, Arita S, Ariyama H, Kusaba H, Baba E, Harada M, Nakano S. , In-vitro schedule-dependent interaction between oxaliplatin and 5-FU in human gastric cancer cell lines. , Anticancer Drugs, 17(4):445-53., 2006.08.
54. Qin B, Tanaka R, Ariyama H, Shibata Y, Arita S, Kusaba H, Baba E, Harada M, Nakano S. , In-vitro differential metabolism and activity of 5-fluorouracil between short-term, high-dose and long-term, low-dose treatments in human squamous carcinoma cells. , Anticancer Drugs. , 17(4):439-43, 2006.08.
55. Yamada Y, Tamura T, Yamamoto N, Shimoyama T, Ueda Y, Murakami H, Kusaba H, Kamiya Y, Saka H, Tanigawara Y, McGovren JP, Natsumeda Y., Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors. , Cancer Chemother Pharmacol. , 58: 173-825., 2006.03.
56. Kusaba H, Ghosh P, Derin R, Buchholz M, Sasaki C, Madara K, Longo DL., IL12-induced interferon-gamma production by human peripheral blood T cells is regulated by mammalian target of rapamycin (mTOR)., J Biol Chem, 280(2),1037-1043, 2005.01.
57. F. Taguchi,H. Kusaba,A. Asai,Y. Iwamoto,K. Yano,H. Nakano,T. Mizukami,N.Saijo,K.Nishio, hnRNP L enhances sensitivity of the cells to KW2189., Int.J.Cancer, 108,679-685, 2004.01.
58. S.Yano, P.Ghosh, H.Kusaba, M.Buchholz, DL.Longo, Effect of promoter methylation of the regulation of IFN-gamma gene during in vitro differentiation of human peripheral blood T cells into a Th2 population., J.Immunology, 171,2510-16, 2003.01.
59. Y.Akiyama,H.Kusaba, F.Kanzawa, T.Tamura, N.Saijo, K.Nishio, Non-cross resistance of ZD0473 in acquired cisplatin-resistant lung cancer cell lines., Lung Cancer, 38, 43-50, 2002.01.
60. K.Hotta,I.Sekine,T.Tamura, M.Sawada,H.Watanabe,H.Kusaba,Y.Akiyama,A.Inoue,T.Shimoyama,H.Nokihara,Y.Ueda,N.Yamamoto,H.Kunitoh,Y.Ohe,T.Kodama,N.Saijo, Phase I/II study of cisplatin and vinorelbine chemotherapy in patients with advanced non-small cell lung cancer., Jpn.J.Clinic.Oncology., 31(12),596-600, 2002.01.
61. H.Kunitoh,Y.Akiyama,H.Kusaba,N.Yamamoto,I.Sekine,Y.Ohe,N.Saijo, A phase I/II trials of cisplatin,docetaxel and ifosmide in advanced or recurrent non-small cell lung cancer., Lung Cancer, 33,259-265, 2001.01.
62. Y.Akiyama,Y.Ohe,T.Tamura,H.Kusaba,N.Yamamoto,I.Sekine,H.Kunitoh,T.Kodama,N.Saijo, A dose escalation study of Paclitaxel and Carboplatin in untreated japanase patients with advanced non-small cell lung cancer., Jpn.J.Clinic.Oncology., 30., 2001.01.
63. J.Nagayama,Y.Tada,T.Harada,H.Kusaba,A.Klue,K.Oshima,M.Kuwano,M.Wada, Retrovirus insertion and transcriptional activation of the multidrug-resistance gene in leukemias treated by a chemotherapeutic agent in vivo., Blood, 10.1182/blood.V97.3.759, 97, 3, 759-766, 97(3),759-766, 2001.01.
64. H.Kusaba,M.Nakayama,T.Harada,M.Nomoto,K.Kohno,M.Kuwano,M.Wada,, Association of 5'CpG demethylation and altered chromatin structure in the promoter region with transcriptional activation of the MDR1 gene in human cancer cells., Eur.J.Biochem., 10.1046/j.1432-1327.1999.00469.x, 262, 3, 924-932, 262,1-10., 1999.01.
65. K.Torigoe,T.Harada,H.Kusaba,T.Uchiumi,K.Kohno,E.D.Green,LC.Tsui,SW.Scherer,D.Schlessinger,M.Kuwano,M.Wada, Localizaion of 67 exons on a YAC contig apanning 1.5Mb around the MDR gene region of humna chromosome 7q21.1., Genomics, 10.1006/geno.1997.5200, 49, 1, 14-22, 49,14-22, 1998.01.
66. M.Nakayama,M.Wada,T.Harada,J.Nagayama,H.Kusaba,K.Oshima,M.Kozuru,H.Komatsu,R.Ueda,M.Kuwano, Hypomethylation status of CpG sites at the promoter region and overexpression of the human MDR1 gene in acute myeloid leukemias., Blood, 92, 11, 4296-4307, 92(11),4296-4307, 1998.01.
67. H.Kusaba,M.Nakayama,T.Harada,K.Torigoe,E.D.Green,SW.Scherer,K.Kohno,M.Kuwano,M.Wada, Maintenance of hypomethylation status and preferential expression of exogenous human MDR1/PGY1 gene in mouse L cells by YAC mediated transfer., Somatic Cell and Molecular Genetics, 10.1007/BF02674417, 23, 4, 259-274, 23(4),259-274, 1997.01.
68. K.Torigoe,S.Sato,H.Kusaba,K.Kohno,M.Kuwano,K.Okumura,E.D.Green,LC.Tsui,SW.Scherer,D.Schlessinger,M.Wada, A YAC-based contig of 1.5Mb spanning the human multidrug resistance gene region and delineating the amplification unit in three human multidrug-resistant cell lines., Genome Research, 10.1101/gr.5.3.233, 5, 3, 233-244, 5(3),233-244, 1995.01.
69. H.Kusaba,K.Kohno,K.Asakuno,M.Kuwano,K.Okumura,E.D.Green,D.Schlessinger,M.Wada, Functional expression of yeast artificial chromosome- human multidrug resistance
genes in mouse cells., Genome Research, 10.1101/gr.5.3.245, 5, 3, 245-258, 5(3),245-258, 1995.01.